Clinical trial timelines in flux: Considerations for U.S. and UK biopharma companies

Clinical trials are a key pillar of the life sciences industry. They are the bridge between scientific discovery and regulatory approval. These trials are also a primary driver of valuation and represent key milestones for investor funding, partnerships and licensing deals. They are essential to demonstrating commercial potential and competitive differentiation for biopharma and biotech companies.

Yet the length of clinical trials has long been seen as a challenge to regulatory approval. As the life sciences industry evolves and regulatory policies shift, will trial periods adjust? Below we dive into clinical trial trends in the U.S. and the UK, examining how they differ as well as what’s to come in both of these geographic landscapes.

What’s driving condensed timelines in the U.S.?

Within the biopharma/biotech sectors, the duration of clinical trials has, on average, ranged from six to 10 years, due to factors such as trial enrollment delays, regulatory requirements and increasingly complex trial protocols.

However, recent data suggests that trial timelines are beginning to shorten. This trend may become the new normal, driven primarily by three factors: artificial intelligence, clinical trial globalization and regulatory changes. 

AI’s impact

Initially, AI was expected to be used primarily for scientific experimentation within the biopharma and biotech sectors; however, AI has also demonstrated significant value by improving operational efficiency and transforming the way clinical trials are designed, executed and scaled. AI is reshaping clinical trials across multiple areas, including:

• Patient recruitment and retention
• Protocol optimization and design
• Data management and monitoring
• Synthetic control arms
• Predictive analyses to accelerate timelines and improve efficiency
• Cost management
• Patient selection to improve trial success rates

Looking forward, AI adoption will be crucial in accelerating clinical trials. Recognizing this shift, the U.S. Food and Drug Administration has issued draft guidance on using AI to support regulatory decision making for drug and biological products, which includes a seven-step, risk-based credibility assessment framework. While this guidance is still in draft form, at least partial adoption is expected, and companies should begin preparing now.

Global reach

Because the FDA allows approvals based solely on foreign clinical data provided certain criteria are met, sponsors are increasingly conducting trials overseas—particularly in China. This shift has contributed to shorter clinical trial timelines.

According to ClinicalTrials.gov, in February more than 50% of registered clinical trials were based solely outside the U.S., with trials based only in the U.S. making up just 29%. Companies are increasingly looking to conduct clinical trials in China due to the country’s lower costs and its ability to shrink timelines through efficient recruitment and execution.

According to a recent report on Asia’s role in biopharma, the timeline from early discovery to investigational new drug is 50% to 70% shorter in China compared to the rest of the world. Further, in later development, trial recruitment, which is often a barrier, is two to five times faster than in the U.S., primarily due to large, concentrated patient pools and well-resourced trial sites. Barring any regulatory changes, companies will likely continue to seek out licensing deals and shift research and development activities to China and other countries outside of the U.S. to save on costs and accelerate timelines.

Regulatory changes

Shorter clinical trial timelines are also being driven by regulatory changes, including regulatory support for decentralized and hybrid trial models in the postpandemic era, which allow for faster enrollment, increased retention and fewer operational bottlenecks. Additionally, the FDA’s expanded use of fast-track designations, breakthrough therapy designations, priority reviews and accelerated approval programs reduces the number of trials required and enables regulatory approvals and key development decisions earlier in the trial process. In February the FDA announced plans to change its default expectation of two pivotal clinical trials to one, which is expected to substantially reduce costs and speed time to market. This change is in line with recent policy changes aimed at reducing drug costs in the U.S.; the agency believes that lowering R&D costs for drug developers will help temper rising drug prices.

Faster trials can mean cost savings and funding opportunities

Clinical trials are extremely costly and often the leading cause of cash burn for biopharma and biotech companies, requiring them to seek financing. While Phase 3 is consistently the costliest phase due to R&D spend, in recent years, many companies have secured financing in Phase 2.

Since investors are more likely to invest on the heels of positive data, many companies seek a financing round when they release Phase 2 data to help fund Phase 3. The funding may come from numerous sources, including venture capital, debt, mergers and acquisitions, and initial public offerings. With several IPO announcements in Q1 2026, capital markets are showing early signs of reopening for the biopharma and biotech sectors. 

With several initial public offerings announcements in Q1 2026, capital markets seem to be showing early signs of reopening for the biopharma and biotech sectors. Phase 2 is seen as the most common point in the clinical trial life cycle to initiate an IPO as it is found to be a sweet spot for attracting investors, while also providing a large source of capital to fund Phase 3 trials.

As clinical trial lifecycles stabilize and shorten, companies can expect to realize cost savings, raise funding more quickly and potentially enter the capital markets sooner. The pace of progress in a clinical trial directly influences funding cadence, and while Phase 2 is expected to continue to attract the greatest investor focus, companies are expected to reach that phase sooner.

Over the coming months, life sciences companies should anticipate that faster, more predictable clinical timelines will increasingly influence development strategy, capital planning and competitive positioning. However, companies should focus on improving execution predictability rather than assuming faster approvals alone will accelerate development. Early regulatory engagement, realistic funding plans and trial designs that account for product complexity will be critical to managing cost, capital needs and development risk.

Organizations that align early around AI-enabled trial execution, global site selection and evolving regulatory expectations will be better equipped to advance assets efficiently and capitalize on funding windows. As clinical development accelerates, disciplined planning and operational readiness will be critical to sustaining momentum and translating speed into long-term value.

Longer UK trials, growing implications

In contrast with U.S.-based trials, UK trial timelines have extended significantly over the past decade. While increasing scientific complexity plays a role, deeper systemic factors are reshaping how quickly trials can be initiated and delivered.

The trend is occurring alongside another concerning signal: the UK’s declining share of global clinical trials since 2016, driven not only by longer timelines but also by post-Brexit regulatory divergence, currency dynamics and growing competition from lower-cost research geographies. Together, these developments point to slower trials and a shift in sponsor perceptions about the UK as a location for clinical research.

Multiple forces are driving longer trial timelines, spanning science, regulation and delivery infrastructure:

The impact on middle market life sciences firms

Longer clinical trial timelines create challenges across the life sciences sector, but the effects are most acute for UK middle market life sciences companies, and include:

Where future growth may emerge

Despite current challenges, several structural trends could support a more efficient and competitive UK clinical trial landscape. To capitalize on these opportunities, companies and investors should consider the following actions. Of these, AI investment is the most consequential: It is the primary lever through which the U.S. is compressing timelines, and the area in which the UK's relative underinvestment is most visible.

These emerging models may favor capital-efficient innovators, specialist contract research organizations and data-driven platforms rather than large pharmaceutical companies. As clinical trial timelines stabilize unevenly across the U.S. and UK, companies should focus on improving execution predictability rather than assuming faster approvals alone will shorten development. Making trials smarter—not merely faster—is the defining challenge for UK sponsors, and that means purposefully adopting AI where it can reduce execution friction. Early regulatory engagement, realistic funding plans, trial designs that account for product complexity and deliberate investment in AI-enabled tooling will be critical to managing cost, capital needs and development risk. The U.S. is ahead on this agenda; the UK need not remain behind.